Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
With biosimilars gaining momentum, Amgen and Allergan cite success of Herceptin's copycat
9 years ago
R&D
The Scangos legacy: A blockbuster MS record with lingering doubts about the pipeline
9 years ago
R&D
Sidelined at the FDA, AstraZeneca watches as new team seizes rival drug in $1.5B Relypsa buyout
9 years ago
R&D
New CEO Szela cuts Aegerion staff again, pulls Juxtapid out of the EU
9 years ago
R&D
BioRegnum: Another great reason emerges for AstraZeneca to target new biotech deals
9 years ago
Bioregnum
Opinion
Merck is scouting sites for a new research hub in the Bay Area, plans new hires
9 years ago
R&D
AstraZeneca culls its neuroscience team, exits Kendall Square office
9 years ago
R&D
By the numbers: 2-year tally of Celgene's biotech partnership deals tops $3B in cash
9 years ago
R&D
AveXis wins the inside track at the FDA with gene therapy ‘breakthrough’
9 years ago
R&D
Synthorx lines up some big synthetic biology R&D goals after grabbing a $10M round
9 years ago
R&D
Beleaguered Zafgen crushed after FDA demands force it to dump lead drug
9 years ago
R&D
Valeant wins first round in $445M gamble on brodalumab approval
9 years ago
R&D
Merck KGaA blueprints a $115M 'collaboration campus' for Massachusetts
9 years ago
R&D
Merck-backed Quartet places biotech vet Gerhard Koenig at the helm
9 years ago
R&D
Celgene signs Jounce as its new biotech star in $2.6B ‘immuno-oncology 2.0’ pact
9 years ago
R&D
Celgene EVP Bagger gets a plum assignment on Trump team
9 years ago
R&D
Biotech vet Gould lands $55M startup round for a new Third Rock platform biotech
9 years ago
R&D
Novartis’ campaign to sweep biosimilar approvals hits a setback
9 years ago
R&D
Brainstorm’s rally fizzles after investors turn sour on questionable ALS data
9 years ago
R&D
Playing defense, Roche loses megafranchise gambit as Gazyva flunks head-to-head with Rituxan
9 years ago
R&D
With cash running low, little Evoke loses a crucial PhIII gamble
9 years ago
R&D
Which big biopharma companies put R&D as their top priority?
9 years ago
R&D
No minister: UK biotech community loses its dedicated government minister
9 years ago
R&D
Ziopharm craters on report of patient death in gene therapy study
9 years ago
R&D
First page
Previous page
1173
1174
1175
1176
1177
1178
1179
Next page
Last page